SCHEMBL26828032

SCHEMBL26828032

c1ccc(-c2ccc(N(c3ccc(-c4ccccc4)cc3)c3cccc(-c4oc5ccccc5c4-c4ccccc4-c4ccccc4)c3)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 6/20 0.40
▸ PLA2G2A P14555 3/20 0.38
▸ PLA2G4A P47712 3/20 0.38
▸ NTRK1 P04629 1/20 0.36
▸ PLK3 Q9H4B4 1/20 0.36
▸ MEN1 O00255 3/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ DDR2 Q16832 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26824379 0.95 L3MBTL1 (0.42) L3MBTL1PLA2G2APLA2G4AMEN1KMT2A
SCHEMBL26828026 0.94 L3MBTL1 (0.40) L3MBTL1PLA2G2APLA2G4ANTRK1PLK3
SCHEMBL26827040 0.90 L3MBTL1 (0.42) L3MBTL1PLA2G2APLA2G4AMEN1KMT2A
SCHEMBL26822380 0.90 L3MBTL1 (0.42) L3MBTL1PLA2G2APLA2G4AMEN1KMT2A
SCHEMBL26824374 0.90 L3MBTL1 (0.45) L3MBTL1PLA2G2APLA2G4AMEN1KMT2A
SCHEMBL26824403 0.90 L3MBTL1 (0.45) L3MBTL1PLA2G2APLA2G4AMEN1KMT2A
SCHEMBL26828034 0.90 L3MBTL1 (0.45) L3MBTL1PLA2G2APLA2G4AMEN1KMT2A
SCHEMBL26827194 0.89 L3MBTL1 (0.41) L3MBTL1PLA2G2APLA2G4AMEN1KMT2A
SCHEMBL26822388 0.89 L3MBTL1 (0.41) L3MBTL1PLA2G2APLA2G4AMEN1KMT2A
SCHEMBL26828030 0.88 L3MBTL1 (0.41) L3MBTL1PLA2G2APLA2G4ANTRK1PLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230389347-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-11-30 — — US disclosed
US-20230389347-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2023-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230389347-A1 COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE LEF1, L1CAM, RER1 L3MBTL1 131/4885PLA2G2A 2543/4885PLA2G4A 3362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback